@acufenero how much say from at (8/10 to a 4/10) did RTG reduce your T?
From 6 or 7/10 to almost no tinnitus, unperceivable even in a quiet room with my fingers on my ears. It lasts for a few hours, while tinnitus comes back gradually.
@acufenero how much say from at (8/10 to a 4/10) did RTG reduce your T?
@acufenero what dosage were you taking?
First time I took 3x300mg for like 3 months, give or take. I do think I developed some tolerance as it didn't lower my tinnitus anymore (it's difficult to measure tinnitus, you know), so I stopped because of this and side effects (it messes so much with your eyes. Luckily, all gone now). A couple of months later I started again with the same conclusions: lowered my tinnitus for a few months, then stopped because of tolerance and side effects.Did you develop a tolerance to Trobalt and if so how long did it to get a tolerance?
Was it effective from the first pill on or did you need to take it for a while before it helped?From 6 or 7/10 to almost no tinnitus, unperceivable even in a quiet room with my fingers on my ears. It lasts for a few hours, while Ttinnituscomes back gradually.
Was it effective from the first pill on or did you need to take it for a while before it helped?
Thanks. Thats interesting. I have some trobalt in my drawer but didn't try it yet. Anecdotes of permanent floaters freaked me out.From the very first one
Not worth it until something comes to the market without any risky side effects.
Trobalt can turn your blue and milky man boobs
The intention is certainly to test RL-81 (a series of compounds) for efficacy vs. tinnitus. The problem tinnitus research is facing is that no pharma company is especially eager to take on a clinical trial pipeline related to tinnitus: the risk of failure (incl. false negative outcome) is too high.Does this mean they will test it for tinnitus? Unclear
Does this mean they will test it for tinnitus? Unclear
The intention is certainly to test RL-81 (a series of compounds) for efficacy vs. tinnitus. The problem tinnitus research is facing is that no pharma company is especially eager to take on a clinical trial pipeline related to tinnitus: the risk of failure (incl. false negative outcome) is too high.
If you are thinking of directly influencing the timeline of the clinical trial itself, then I don't believe there is anything that can be done considering:@attheedgeofscience Is there something that we as a community can do to expedite this process? I am so sick of inaction, and If pharmaceutical companies won't help us, then we must revert to helping ourselves right?
It is fully understandable that slow progress can be frustrating. But finding effective treatments for medical conditions is not limited to tinnitus: there are many maladies that don't don't have good therapies. Tinnitus is but one of them...Isn't Allergan backing the research as stated in the pr?
By the way, do you think that these kind of approaches can "cure" tinnitus (that is, shut the ringing down) after taking the drug for some time? Or are they more likely to be taken on a daily basis?
The answer to how much it costs is:How much does taking a medicine all the way though clinical testing cost? I know this is a big question and probably unrealistic. But maybe it's a discussion we need to have on here to form something?
Yes: generally, an investor buying a "standard" investment e.g. one that you can invest in via a financial institution would ask for a higher return on investment (ROI) if it carries a higher risk. But investing in a clinical trial product candidate isn't a standard investment. And higher risk doesn't necessarily carry a higher reward (in this regard) because that would depend on the medical need and market cost (which determine the market value). Put another way: there are many other diseases (than tinnitus) that are worth pursuing therapies for and which at the same time would also be a good investment (due to high medical need). So from the investor point-of-view: why take a chance on finding a cure for tinnitus when there are so many other areas of interest that could be considered?Suppose with any investment
Higher risk = Higher reward
Lower risk = lower reward
Yes: generally, an investor buying a "standard" investment e.g. one that you can invest in via a financial institution would ask for a higher return on investment (ROI) if it carries a higher risk. But investing in a clinical trial product candidate isn't a standard investment. And higher risk doesn't necessarily carry a higher reward (in this regard) because that would depend on the medical need and market cost (which determine the market value). Put another way: there are many other diseases (than tinnitus) that are worth pursuing therapies for and which at the same time would also be a good investment (due to high medical need). So from the investor point-of-view: why take a chance on finding a cure for tinnitus when there are so many other areas of interest that could be considered?
Unlike what you're implying here, I didn't make anything up. Couldn't you read the press release that I linked?For the same reasons, I can also confirm that Allergan is not one of the pharma entities in question (unlike what is suggested here recently):
Sure, I can read it: I have just now and also when it was released about a year ago. However, here is what you wrote:Unlike what you're implying here, I didn't make anything up. Couldn't you read the press release that I linked?
That compound was developed Glaxosmithkline (very very big pharma) and while I can't be sure, I would suspect that was removed due to poor performance in the market and an already oversaturated market for epilepsy pharmaceuticals. You can see their R&D pipeline here https://www.gsk.com/en-gb/investors/product-pipeline/And what about trobalt / retigabine. Where those two medicines not backed by big pharma? And if that was so, why not back a redesigned drug that should work a lot better than the ones that they already backed? Was that just because the first two medicines weren't sold enough, and they see they might not be able to recoup their financial investment?